Hormone Therapy and the FDA Boxed Warning: What Changed and What It Means for You

Woman smiling beside a rustic stone doorway with a green landscape in the background.

In November 2025, the FDA announced major changes to boxed warnings on menopausal hormone therapy. Here's what changed, why timing matters, and what it means for your treatment options.

Menopausal hormone therapy (also called MHT or HRT) has been one of the most controversial treatments in women’s health. For more than 20 years, a boxed warning shaped how patients and clinicians viewed estrogen and progesterone. With much of that warning now removed, what should you know if you're considering hormone therapy today?

Why Hormone Therapy Got a Boxed Warning

The boxed warnings followed findings from the Women’s Health Initiative (WHI), a large study that began reporting results in 2002. Concerns about breast cancer, cardiovascular disease, blood clots, stroke, and dementia contributed to widespread caution around hormone therapy and a significant decline in prescriptions.

But the WHI included many women who were older or several years past menopause. The warning didn’t distinguish between age, timing of starting treatment, route of delivery, or type of hormone. As a result, many women avoided treatment even when they were struggling with severe hot flashes, sleep disruption, and vaginal dryness.

What We Know Now About Safety

Timing matters. Starting hormone therapy before age 60 or within 10 years of menopause is generally associated with a more favorable balance of benefits and risks for otherwise healthy women without contraindications. This is often called the “window of opportunity.” During this window, the balance of benefits and risks is generally more favorable, particularly for symptom relief and bone protection.

Breast cancer risk is also more nuanced than the original warning suggested. It depends on:

The type of hormone therapy
When treatment is started
Your individual risk factors

What the FDA Changed

The FDA’s updated labeling approach reflects a more individualized understanding of hormone therapy’s benefits and risks.

Updated boxed warnings. The FDA removed statements about cardiovascular disease, breast cancer, and probable dementia from boxed warnings on affected hormone therapy products. Important safety information about cardiovascular and breast cancer risks remains elsewhere in product labeling.
Treatment duration is individualized. The previous labeling recommendation to use the lowest effective dose for the shortest duration was removed. Treatment decisions should still consider symptoms, personal risk factors, and ongoing evaluation.
Timing matters. Updated labeling emphasizes considering systemic hormone therapy before age 60 or within 10 years of menopause for moderate to severe symptoms.
An important warning remains. Systemic estrogen-only products retain a boxed warning about endometrial cancer. Patients with a uterus generally require a progestogen when using systemic estrogen to help protect the uterine lining.

So, Is Hormone Therapy Safe?

Removing the warning doesn’t make hormone therapy risk-free. It means the old warning was too broad to reflect current evidence. Your risk depends on your age when you start treatment, how long it’s been since menopause, the type and route of hormone therapy, and your personal history of cardiovascular disease, blood clots, and cancer. Modern menopause care favors individualized decisions over blanket avoidance.

When appropriately prescribed, hormone therapy remains one of the most effective treatments for menopausal hot flashes and night sweats. It may also improve related sleep disturbances and can help prevent bone loss and reduce fracture risk. Local vaginal estrogen can be especially helpful for vaginal dryness and other genitourinary symptoms.

Is It Right for You?

The best decision comes from a conversation about your symptoms, your history, and your goals. If you’re wondering whether hormone therapy fits, we’d be glad to walk through it with you. Book an appointment.

References:

Manson JE, et al. JAMA. 2024;331(20):1748-1760. doi:10.1001/jama.2024.6542
Bofill Rodriguez M, et al. Cochrane Database Syst Rev. 2025;(11):CD004143. doi:10.1002/14651858.CD004143.pub6
Sriprasert I, et al. Obstet Gynecol. 2026;147(5):642-646. doi:10.1097/AOG.0000000000006226
Buchanan LA, et al. Menopause. 2026. doi:10.1097/GME.0000000000002793
Pinkerton JV. N Engl J Med. 2020;382(5):446-455. doi:10.1056/NEJMcp1714787
Lambrinoudaki I, et al. J Clin Endocrinol Metab. 2026;111(4):e974-e994. doi:10.1210/clinem/dgaf638
NAMS 2022 Hormone Therapy Position Statement. Menopause. 2022;29(7):767-794. doi:10.1097/GME.0000000000002028